Rand Murshidi, Salsabiela Bani Hamad, Assem Al Refaei, Nour Shewaikani, Moayad Shaf'ei, Sara N Alshoubaki, Tala A Haddad, Tawfiq Khasawneh, Taima Fkheideh, Mahmoud Abdallat
{"title":"对接受异维A酸治疗的痤疮患者进行风险分层的新型预测方法:对实验室异常和炎症参数变化的分析。","authors":"Rand Murshidi, Salsabiela Bani Hamad, Assem Al Refaei, Nour Shewaikani, Moayad Shaf'ei, Sara N Alshoubaki, Tala A Haddad, Tawfiq Khasawneh, Taima Fkheideh, Mahmoud Abdallat","doi":"10.1080/09546634.2023.2301435","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Isotretinoin is a widely used, effective medication for moderate to severe acne. It is typically used for several months, which necessitates regular laboratory monitoring. However, consensus on the optimal assessment frequency is lacking.</p><p><strong>Method: </strong>This is a single-center retrospective study on 1182 patients who received isotretinoin for acne at the Dermatology Clinic in Jordan University Hospital over 5 years.</p><p><strong>Results: </strong>Of the 1182 patients, 892 (76.57% females) met the inclusion criteria. An increase in the proportion of patients with abnormal triglycerides and total cholesterol levels from baseline to the sixth month was observed (<i>p</i> < 0.05). Conversely, differences in the number of patients with abnormal AST, ALT, and CBC were not found throughout treatment (<i>p</i> > 0.05). Moreover, there was a decrease in the neutrophil-to-lymphocyte ratio (NLR) ratio and systemic inflammatory index (SII) after the sixth month of isotretinoin treatment compared to the baseline (<i>p</i> = 0.012 and <i>p</i> = 0.021, respectively).</p><p><strong>Conclusions: </strong>We found that a baseline cholesterol level of 163.9 mg/dl and a baseline triglycerides level of 85.5 mg/dL are highly specific and sensitive in detecting grade 1 abnormalities at the one-month follow-up. This novel prediction approach serves as an effective risk stratification method for isotretinoin acne patients.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"35 1","pages":"2301435"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A novel predictive method for risk stratification in acne patients receiving isotretinoin: an analysis of laboratory abnormalities and changes in inflammatory parameters.\",\"authors\":\"Rand Murshidi, Salsabiela Bani Hamad, Assem Al Refaei, Nour Shewaikani, Moayad Shaf'ei, Sara N Alshoubaki, Tala A Haddad, Tawfiq Khasawneh, Taima Fkheideh, Mahmoud Abdallat\",\"doi\":\"10.1080/09546634.2023.2301435\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Isotretinoin is a widely used, effective medication for moderate to severe acne. It is typically used for several months, which necessitates regular laboratory monitoring. However, consensus on the optimal assessment frequency is lacking.</p><p><strong>Method: </strong>This is a single-center retrospective study on 1182 patients who received isotretinoin for acne at the Dermatology Clinic in Jordan University Hospital over 5 years.</p><p><strong>Results: </strong>Of the 1182 patients, 892 (76.57% females) met the inclusion criteria. An increase in the proportion of patients with abnormal triglycerides and total cholesterol levels from baseline to the sixth month was observed (<i>p</i> < 0.05). Conversely, differences in the number of patients with abnormal AST, ALT, and CBC were not found throughout treatment (<i>p</i> > 0.05). Moreover, there was a decrease in the neutrophil-to-lymphocyte ratio (NLR) ratio and systemic inflammatory index (SII) after the sixth month of isotretinoin treatment compared to the baseline (<i>p</i> = 0.012 and <i>p</i> = 0.021, respectively).</p><p><strong>Conclusions: </strong>We found that a baseline cholesterol level of 163.9 mg/dl and a baseline triglycerides level of 85.5 mg/dL are highly specific and sensitive in detecting grade 1 abnormalities at the one-month follow-up. This novel prediction approach serves as an effective risk stratification method for isotretinoin acne patients.</p>\",\"PeriodicalId\":94235,\"journal\":{\"name\":\"The Journal of dermatological treatment\",\"volume\":\"35 1\",\"pages\":\"2301435\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of dermatological treatment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/09546634.2023.2301435\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatological treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09546634.2023.2301435","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
简介异维A酸是一种广泛使用的治疗中重度痤疮的有效药物。该药通常使用数月,因此需要定期进行实验室监测。然而,对于最佳的评估频率还缺乏共识:这是一项单中心回顾性研究,研究对象是约旦大学医院皮肤科诊所 5 年来接受异维A酸治疗痤疮的 1182 名患者:在1182名患者中,892人(76.57%为女性)符合纳入标准。从基线到第六个月,观察到甘油三酯和总胆固醇水平异常的患者比例有所增加(P P > 0.05)。此外,与基线相比,异维A酸治疗第六个月后,中性粒细胞与淋巴细胞比率(NLR)和全身炎症指数(SII)有所下降(分别为 p = 0.012 和 p = 0.021):我们发现,基线胆固醇水平为 163.9 mg/dL 和基线甘油三酯水平为 85.5 mg/dL 在一个月的随访中对检测 1 级异常具有高度的特异性和敏感性。这种新颖的预测方法是异维A酸痤疮患者进行风险分层的有效方法。
A novel predictive method for risk stratification in acne patients receiving isotretinoin: an analysis of laboratory abnormalities and changes in inflammatory parameters.
Introduction: Isotretinoin is a widely used, effective medication for moderate to severe acne. It is typically used for several months, which necessitates regular laboratory monitoring. However, consensus on the optimal assessment frequency is lacking.
Method: This is a single-center retrospective study on 1182 patients who received isotretinoin for acne at the Dermatology Clinic in Jordan University Hospital over 5 years.
Results: Of the 1182 patients, 892 (76.57% females) met the inclusion criteria. An increase in the proportion of patients with abnormal triglycerides and total cholesterol levels from baseline to the sixth month was observed (p < 0.05). Conversely, differences in the number of patients with abnormal AST, ALT, and CBC were not found throughout treatment (p > 0.05). Moreover, there was a decrease in the neutrophil-to-lymphocyte ratio (NLR) ratio and systemic inflammatory index (SII) after the sixth month of isotretinoin treatment compared to the baseline (p = 0.012 and p = 0.021, respectively).
Conclusions: We found that a baseline cholesterol level of 163.9 mg/dl and a baseline triglycerides level of 85.5 mg/dL are highly specific and sensitive in detecting grade 1 abnormalities at the one-month follow-up. This novel prediction approach serves as an effective risk stratification method for isotretinoin acne patients.